SCHEMBL1105227

SCHEMBL1105227

CCCCCCCCCCCCCCCCOCCOP1(=O)CO[C@@H](Cn2cnc(N)nc2=O)CO1

nearest known ligand 0.70

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 5/20 0.70
ALDH1A1 P00352 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
EP300 Q09472 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20638642 0.90 FGFR1 (0.67) FGFR1
SCHEMBL20638629 0.88 FGFR1 (0.64) FGFR1
SCHEMBL14510063 0.85 FGFR1 (0.56) FGFR1ALDH1A1EP300
SCHEMBL14510064 0.83 FGFR1 (0.54) FGFR1ALDH1A1
SCHEMBL22481895 0.82 FGFR1 (0.56) FGFR1
SCHEMBL138629 0.82 FGFR1 (1.00) FGFR1ALDH1A1TDP1EP300
SCHEMBL26772803 0.81 FGFR1 (0.63) FGFR1
SCHEMBL20644347 0.81 FGFR1 (0.54) FGFR1
SCHEMBL1135969 0.81 FGFR1 (0.50) FGFR1ALDH1A1EP300
SCHEMBL26772804 0.80 FGFR1 (0.60) FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153787-B2 Azacytosine derivatives useful as antiviral agents K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2012-04-10 US disclosed
US-20090005346-A1 Azacytosine Derivatives Useful as Antiviral Agents K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005346-A1 Azacytosine Derivatives Useful as Antiviral Agents ITPA, ZC3HAV1, MTAP FGFR1 4874/4885ALDH1A1 1877/4885TDP1 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.